VISEN Pharmaceuticals (HKG:2561)

Hong Kong · Delayed Price · Currency is HKD

19.98

-0.02 (-0.10%)

Aug 27, 2026, 3:34 PM HKT

-56.77% (1Y)

Market Cap	2.18B -54.9%
Revenue (ttm)	151.34K -95.1%
Net Income	-282.01M
EPS	-2.72
Shares Out	109.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,600
Open	20.00
Previous Close	20.00
Day's Range	19.81 - 20.00
52-Week Range	18.50 - 47.10
Beta	n/a
Analysts	Buy
Price Target	51.88 (+159.66%)
Earnings Date	Aug 27, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia, that is in phase 2 clinical trial; and Palopegteriparatide, a once-daily parath... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2018

Employees 82

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2561

Full Company Profile

Financial Performance

In 2025, VISEN Pharmaceuticals's revenue was 136,000, a decrease of -95.10% compared to the previous year's 2.78 million. Losses were -253.42 million, 39.1% more than in 2024.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2561 stock is "Buy." The 12-month stock price target is $51.88, which is an increase of 159.66% from the latest price.

Price Target

$51.88

(159.66% upside)

Analyst Consensus: Buy

Stock Forecasts